Edition:
India

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

12.30USD
1:30am IST
Change (% chg)

$-1.14 (-8.48%)
Prev Close
$13.44
Open
$13.44
Day's High
$13.44
Day's Low
$12.28
Volume
255,720
Avg. Vol
280,004
52-wk High
$15.59
52-wk Low
$3.16

Select another date:

Wed, Apr 11 2018

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

BRIEF-Cymabay Reports Q4 Loss Per Share $0.11

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock

* CYMABAY THERAPEUTICS INC - ‍ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR​ Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

Select another date: